1. Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study
- Author
-
Ha Yeong Gil, Seong Hoon Shin, Hyung Eun Park, Soo Mee Bang, Yoon Ji Choi, Min Hee Hong, Jin Seok Ahn, So Yeon Oh, Jin Ho Baek, Eun Lyeong Park, Young Joo Kim, Jin Hyoung Kang, and Juneyoung Lee
- Subjects
Male ,lcsh:Diseases of the circulatory (Cardiovascular) system ,medicine.medical_specialty ,medicine.drug_class ,Deep vein ,venous thromboembolism ,Administration, Oral ,Low molecular weight heparin ,Hemorrhage ,030204 cardiovascular system & hematology ,direct oral anticoagulants ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Recurrence ,Risk Factors ,Neoplasms ,Internal medicine ,Republic of Korea ,medicine ,Humans ,cancer ,cardiovascular diseases ,low-molecular-weight heparin ,Aged ,Retrospective Studies ,business.industry ,Incidence (epidemiology) ,Anticoagulants ,Cancer ,Retrospective cohort study ,Hematology ,General Medicine ,Heparin ,Heparin, Low-Molecular-Weight ,Middle Aged ,medicine.disease ,Thrombosis ,Pulmonary embolism ,Treatment Outcome ,medicine.anatomical_structure ,lcsh:RC666-701 ,030220 oncology & carcinogenesis ,Female ,Original Article ,Pulmonary Embolism ,business ,medicine.drug - Abstract
This study assessed epidemiologic data and clinical outcomes, including venous thromboembolism (VTE) recurrence and bleeding events, in patients with cancer-associated VTE, and assessed factors associated with clinical outcomes. Data were extracted from retrospective medical-chart review of adult patients diagnosed with cancer-associated deep vein thrombosis or pulmonary embolism who received anticoagulation treatment for ≥3 months. Patients were classified by: low-molecular-weight heparin (LMWH), direct oral anticoagulants (DOACs), and other anticoagulants. First VTE recurrence and bleeding events, and factors associated with their occurrence, were assessed during the initial 6 months of treatment. Overall, 623 patients (age: 63.7 ± 11.3 years, 49.3% male) were included (119, 132, and 372 patients in LMWH, DOACs and other anticoagulants groups, respectively). The cumulative 6-month incidence of VTE recurrence was 16.6% (total), 8.3% (LMWH), 16.7% (DOACs), and 20.7% (other); respective bleeding events were 22.5%, 11.0%, 12.3%, and 30.7%). VTE recurrence and bleeding rates differed only between LMWH and other anticoagulants (HR 2.4, 95% CI: 1.2-5.0 and 3.6, 1.9-6.8, respectively). These results highlight the importance of initial VTE treatment choice for preventing VTE recurrence and bleeding events. LMWH or DOACs for ≥3 months can be considered for effective VTE management in cancer patients.
- Published
- 2021
- Full Text
- View/download PDF